Kanghong Pharmaceutical announced that its subsidiary Hongji Biotech has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials of KH631 ophthalmic injection suitable for the treatment of diabetic macular edema. KH631 ophthalmic injection is an innovative gene therapy product independently developed by Hongji Biotech. It is a class 1 of therapeutic biological products. The product is based on an adeno-associated virus delivery system with independent intellectual property rights, and is characterized in terms of tissue specificity, immunogenicity, controllability of expression, and infection efficiency, and has shown continuous efficacy in preclinical disease models.

Kanghong Pharmaceutical announced that its subsidiary Hongji Biotech has received the “Drug Clinical Trial Approval Notice” issued by the State Drug Administration and agreed to carry out clinical trials of KH631 ophthalmic injection suitable for the treatment of diabetic macular edema. KH631 ophthalmic injection is an innovative gene therapy product independently developed by Hongji Biotech. It is a class 1 of therapeutic biological products. The product is based on an adeno-associated virus delivery system with independent intellectual property rights, and is characterized in terms of tissue specificity, immunogenicity, controllability of expression, and infection efficiency, and has shown continuous efficacy in preclinical disease models.